The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program
Harms M, Cho K, Anticevic A, Bolo N, Bouix S, Campbell D, Cannon T, Cecchi G, Goncalves M, Haidar A, Hughes D, Izyurov I, John O, Kapur T, Kim N, Kotler E, Kubicki M, Kuperman J, Laulette K, Lindberg U, Markiewicz C, Ning L, Poldrack R, Rathi Y, Romo P, Tamayo Z, Wannan C, Wickham A, Yassin W, Zhou J, Addington J, Alameda L, Arango C, Breitborde N, Broome M, Cadenhead K, Calkins M, Chen E, Choi J, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Ellman L, Fusar-Poli P, Gaspar P, Gerber C, Glenthøj L, Horton L, Hui C, Kambeitz J, Kambeitz-Ilankovic L, Keshavan M, Kim S, Koutsouleris N, Kwon J, Langbein K, Mamah D, Mathalon D, Mittal V, Nordentoft M, Pearlson G, Perez J, Perkins D, Powers A, Rogers J, Sabb F, Schiffman J, Shah J, Silverstein S, Smesny S, Stone W, Strauss G, Thompson J, Upthegrove R, Verma S, Wang J, Wolf D, Kahn R, Kane J, McGorry P, Nelson B, Woods S, Shenton M, Wood S, Bearden C, Pasternak O. The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program. Schizophrenia 2025, 11: 52. PMID: 40175382, PMCID: PMC11965426, DOI: 10.1038/s41537-025-00581-6.Peer-Reviewed Original ResearchClinical high riskSchizophrenia ProgramClinical high-risk cohortClinical high-risk stateResting-state fMRIFMRI scanningStudy of individualsNeuroimaging resultsBrain regionsNeuroimaging dataNeuroimaging protocolsStructural scansParticipation varianceDiffusion scansFMRIPercentage of participantsNeuroimagingVariance component analysisMulti-siteParticipantsPsychosisVarianceTime pointsDiffusion-weighted imagingHigh risk
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply